Find Mazdutide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ibi362, Glxc-26803, 2259884-03-0
Molecular Formula
C207H317N45O65
Molecular Weight
4476  g/mol
InChI Key
XRBYWQZGSZWYEJ-HMQIFOERSA-N

Mazdutide
1 2D Structure

Mazdutide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
2.1.2 InChI
InChI=1S/C207H317N45O65/c1-116(2)93-144(189(295)230-138(70-76-168(271)272)179(285)221-107-162(264)219-109-166(268)252-86-46-57-157(252)201(307)245-154(110-253)181(287)220-106-159(213)261)234-190(296)145(94-117(3)4)236-194(300)151(100-127-104-218-133-52-37-36-51-131(127)133)240-188(294)142(73-79-171(277)278)233-202(308)174(119(7)8)249-197(303)149(96-123-47-30-28-31-48-123)238-187(293)141(72-78-170(275)276)231-183(289)135(56-41-45-83-215-164(266)113-316-91-90-315-88-85-217-165(267)114-317-92-89-314-87-84-216-160(262)75-69-143(205(311)312)225-161(263)58-34-26-24-22-20-18-16-14-15-17-19-21-23-25-27-35-59-167(269)270)226-177(283)120(9)224-182(288)134(53-38-42-80-208)227-184(290)136(54-39-43-81-209)228-186(292)140(71-77-169(273)274)232-195(301)152(102-172(279)280)241-191(297)146(95-118(5)6)235-192(298)147(98-125-60-64-129(258)65-61-125)237-185(291)137(55-40-44-82-210)229-199(305)155(111-254)244-193(299)148(99-126-62-66-130(259)67-63-126)239-196(302)153(103-173(281)282)242-200(306)156(112-255)246-204(310)176(122(11)257)250-198(304)150(97-124-49-32-29-33-50-124)243-203(309)175(121(10)256)248-163(265)108-222-180(286)139(68-74-158(212)260)247-206(313)207(12,13)251-178(284)132(211)101-128-105-214-115-223-128/h28-33,36-37,47-52,60-67,104-105,115-122,132,134-157,174-176,218,253-259H,14-27,34-35,38-46,53-59,68-103,106-114,208-211H2,1-13H3,(H2,212,260)(H2,213,261)(H,214,223)(H,215,266)(H,216,262)(H,217,267)(H,219,264)(H,220,287)(H,221,285)(H,222,286)(H,224,288)(H,225,263)(H,226,283)(H,227,290)(H,228,292)(H,229,305)(H,230,295)(H,231,289)(H,232,301)(H,233,308)(H,234,296)(H,235,298)(H,236,300)(H,237,291)(H,238,293)(H,239,302)(H,240,294)(H,241,297)(H,242,306)(H,243,309)(H,244,299)(H,245,307)(H,246,310)(H,247,313)(H,248,265)(H,249,303)(H,250,304)(H,251,284)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,311,312)/t120-,121+,122+,132-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,174-,175-,176-/m0/s1
2.1.3 InChI Key
XRBYWQZGSZWYEJ-HMQIFOERSA-N
2.1.4 Canonical SMILES
CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC8=CNC=N8)N
2.1.5 Isomeric SMILES
C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC8=CNC=N8)N)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Ibi362

2. Ly3305677

2.2.2 Depositor-Supplied Synonyms

1. Ibi362

2. Glxc-26803

3. 2259884-03-0

2.3 Create Date
2023-03-27
3 Chemical and Physical Properties
Molecular Weight 4476 g/mol
Molecular Formula C207H317N45O65
XLogP3-12.6
Hydrogen Bond Donor Count58
Hydrogen Bond Acceptor Count70
Rotatable Bond Count164
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area1750
Heavy Atom Count317
Formal Charge0
Complexity10500
Isotope Atom Count0
Defined Atom Stereocenter Count31
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in patients with Type 2 Diabetes.


Lead Product(s): Mazdutide

Therapeutic Area: Endocrinology Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 01, 2024

blank

01

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in patients with Type 2 Diabetes.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

August 01, 2024

blank

Details:

IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.


Lead Product(s): Mazdutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Eli Lilly

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 23, 2024

blank

02

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

July 23, 2024

blank

Details:

IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.


Lead Product(s): Mazdutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 27, 2024

blank

03

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 27, 2024

blank

Details:

IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for Type 2 Diabetes


Lead Product(s): Mazdutide

Therapeutic Area: Endocrinology Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2024

blank

04

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for Type 2 Diabetes

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

May 08, 2024

blank

Details:

IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.


Lead Product(s): Mazdutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 07, 2024

blank

05

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

February 07, 2024

blank

Details:

IBI362 (mazdutide) is a GLP-1R and GCGR dual agonist. It is under phase 3 clinical development for the treatment of adults with overweight or obesity.


Lead Product(s): Mazdutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Eli Lilly

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2024

blank

06

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a GLP-1R and GCGR dual agonist. It is under phase 3 clinical development for the treatment of adults with overweight or obesity.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

January 08, 2024

blank

Details:

IBI362 (mazdutide) is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, which is under phase 3 clinical development for the treatment of obesity.


Lead Product(s): Mazdutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Eli Lilly

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 01, 2024

blank

07

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, which is under phase 3 clinical development for the treatment of obesity.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

January 01, 2024

blank

Details:

IBI362 (Mazdutide) is a GLP-1R and GCGR dual agonist peptide, subcutaneous injection, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.


Lead Product(s): Mazdutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 29, 2023

blank

08

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (Mazdutide) is a GLP-1R and GCGR dual agonist peptide, subcutaneous injection, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

October 29, 2023

blank

Details:

IBI362 (mazdutide) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.


Lead Product(s): Mazdutide

Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2023

blank

09

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

May 11, 2023

blank

Details:

IBI362 (mazdutide) is a long-acting synthetic peptide, having GLP-1R and GCGR dual agonistic action, mimicking the effects of endogenous oxyntomodulin which promotes insulin secretion, lowering blood glucose and reducing body weight.


Lead Product(s): Mazdutide

Therapeutic Area: Endocrinology Brand Name: IBI362

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2023

blank

10

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : IBI362 (mazdutide) is a long-acting synthetic peptide, having GLP-1R and GCGR dual agonistic action, mimicking the effects of endogenous oxyntomodulin which promotes insulin secretion, lowering blood glucose and reducing body weight.

Brand Name : IBI362

Molecule Type : Peptide

Upfront Cash : Not Applicable

January 10, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty